CLLS250117P5000
- 0.00
- 0.000.00%
Cellectis Newsroom
Citi Maintains Cellectis(CLLS.US) With Buy Rating, Cuts Target Price to $11
Cellectis Draws Down Final Tranche of EUR40 Million Loan From European Investment Bank
Press Release: Cellectis Announces the Drawdown of the Third Tranche of EUR5 Million Under the Credit Facility Agreement Entered With the European Investment Bank (EIB)
Gene Editing Market Forecast Report 2024, With Profiles of Merck, GenScript, Revvity, Lonza, Precision BioSciences, Cellectis, AMSBIO, Synthego, Takara Bio, Bio-Techne, Reprocell and More
European Equities Traded in the US as American Depositary Fall Sharply in Tuesday Trading
Promising Partnership and Pipeline Propel Cellectis SA to a Buy Rating
Monthly Information on Share Capital and Company Voting Rights
Earnings Call: Cellectis Reports Robust Cash Reserves, New R&D Initiatives
Express News | Cellectis SA : Barclays Cuts Target Price to $5 From $7
Barclays Maintains Cellectis(CLLS.US) With Buy Rating, Maintains Target Price $5
JMP Securities Maintains Cellectis(CLLS.US) With Buy Rating, Maintains Target Price $6
Cellectis SA: Financial Growth Amidst Strategic Partnerships
Cellectis SA Advances CAR T-cell Therapy for Solid Tumors
Cellectis Presents Multiple Strategies To Enhance CAR T-Cell Efficacy In Solid Tumors At The SITC Annual Meeting
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript Summary
Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript
Cellectis Is Maintained at Overweight by Barclays
Cellectis Analyst Ratings
Barclays Maintains Cellectis(CLLS.US) With Buy Rating, Cuts Target Price to $5